PCM
HZNP

Pentwater Capital Management’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Pentwater Capital Management’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-100,000
Closed -$10.3M – 162
2023
Q2 		$10.3M Buy
+100,000
New +$10.6M 0.07% 58
2023
Q1 		– Sell
-120,000
Closed -$13.7M – 189
2022
Q4 		$13.7M Buy
+120,000
New +$9.97M 0.24% 47

Other funds holding HZNP

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
VWA
Valued Wealth Advisors Holladay, Utah $275M AUM 24.94% 1-Year Est. Return
FSWA
Financial Synergies Wealth Advisors Houston, Texas $1.18B AUM 31.41% 1-Year Est. Return
BCMLT
Beacon Capital Management LLC (Tennessee) Franklin, Tennessee $683M AUM 22.58% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Pentwater Capital Management's HZNP Position: Q4 2023 in Review

Pentwater Capital Management sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2023, closing a stake of 15,552,000 shares — an estimated $1.8B sold.

Pentwater Capital Management first reported a position in HZNP in Q3 2015 and held it in 5 quarters. The position peaked at $1.8B in Q3 2023. 6 funds tracked by Wall St. Rank hold HZNP as of Q4 2023.

  • Pentwater Capital Management reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2023 after selling out during the quarter.
  • Pentwater Capital Management sold 15,552,000 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2023, an estimated $1.8B.
  • Pentwater Capital Management first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q3 2015 and held it in 5 quarters.
  • Pentwater Capital Management's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $1.8B in Q3 2023.
  • 6 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2023.

Based on Pentwater Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.